Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Lebrikizumab en melfalan flufenamide in de sluis geplaatst
dec 2023 | Eczeem, MM
okt 2020
apr 2020 | Transplantatie
apr 2020
jan 2020 | Leukemie